Alphamab Oncology

Informe acción SEHK:9966

Capitalización de mercado: HK$3.7b

Salud financiera de hoja de balance de Alphamab Oncology

Salud financiera controles de criterios 5/6

Alphamab Oncology has a total shareholder equity of CN¥1.6B and total debt of CN¥320.0M, which brings its debt-to-equity ratio to 19.6%. Its total assets and total liabilities are CN¥2.1B and CN¥513.3M respectively.

Información clave

19.6%

Ratio deuda-patrimonio

CN¥320.00m

Deuda

Ratio de cobertura de interesesn/a
EfectivoCN¥1.46b
PatrimonioCN¥1.63b
Total pasivoCN¥513.25m
Activos totalesCN¥2.14b

Actualizaciones recientes sobre salud financiera

Recent updates

Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable

Sep 30
Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable

Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding

Jun 20
Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding

Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

May 06
Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Mar 13
Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Jan 17
Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

May 21
Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Mar 01
Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Oct 04
Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Is Alphamab Oncology (HKG:9966) A Risky Investment?

May 21
Is Alphamab Oncology (HKG:9966) A Risky Investment?

Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt

Oct 05
Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt

Is Alphamab Oncology (HKG:9966) Using Too Much Debt?

May 05
Is Alphamab Oncology (HKG:9966) Using Too Much Debt?

Análisis de la situación financiera

Pasivos a corto plazo: 9966's short term assets (CN¥1.6B) exceed its short term liabilities (CN¥345.4M).

Pasivo a largo plazo: 9966's short term assets (CN¥1.6B) exceed its long term liabilities (CN¥167.9M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: 9966 has more cash than its total debt.

Reducción de la deuda: 9966 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 9966 has sufficient cash runway for more than 3 years based on its current free cash flow.

Pronóstico de cash runway: Insufficient data to determine if 9966 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Descubre empresas con salud financiera